Krishnan Nandabalan, Director, 10% Owner at BioXcel Therapeutics, Inc. (BTAI), sold 60,000 shares at $17.32 ($1.0M) on 2023-04-06, disclosed to the SEC on 2023-04-10.
Scheduled sale ($1.0M) by Director, 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BTAI | SELL | 2021-06-29 | $29.2M | — | Filing → |
| BTAI | BUY | 2018-11-30 | $5K | — | Filing → |